Monday, 16 November 2026LatestVideosAboutContact
Latest
Nvidia shares primed to steady as investors eye Huang's comeback reportIran Mocks US War Rhetoric, Invokes Roman DefeatMumbai Chhath Puja News: Faith Takes Over Juhu Beach as Devotees Offer Prayers Amid Sea WavesFRND’s profit jumps nearly tenfold to ₹19.27 crore as revenue rises 88%Bihar Chhath Puja News: Devotees Offer Morning Arghya at Patna's Kachchi Talab Ghat DescriptionAll smiles for Ronaldinho as Brazil great returns to club football at age 46Rupee rises 6 paise to 94.13 against U.S. dollar in early tradeChina’s factory output slows to 4.8% in October as retail sales growth weakensIndia deserves re-rating; Sensex may hit 95,000 by Dec 2027: Morgan StanleyKinetic Engineering Shifts Into Top Gear In Q2, Revenue Zooms 99% To ₹78.31 Crore As Company Returns To ProfitChhath Puja 2026 Concludes As Devotees Offer Usha Arghya To Rising Sun At Ghats Across India | VideoMumbai: Chhatrapati Shivaji Maharaj's Historic Wagh Nakh On Display At CSMVS; Check Museum Visit Timings And Entry Details
BusinessUpdated 26 min ago

Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar

Image: Business Standard

Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo's earliest licensed US launch in 2028.

Continue reading on Business Standard

Hello Headlines links you to the original publisher for the full story.

Read full story

More in Business

See all